Cantor Fitzgerald Estimates uniQure FY2026 Earnings

uniQure (NASDAQ:QURE) – Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of uniQure in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the biotechnology company will earn ($1.99) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share.

Several other equities analysts also recently weighed in on the company. Guggenheim reissued a “buy” rating and set a $28.00 price target on shares of uniQure in a research report on Monday, May 12th. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, May 24th. Chardan Capital restated a “buy” rating and set a $38.00 target price on shares of uniQure in a research report on Friday, May 30th. Wells Fargo & Company decreased their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. Finally, HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of uniQure in a research report on Thursday, May 29th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and an average price target of $37.82.

uniQure Trading Down 3.3%

Shares of uniQure stock opened at $16.34 on Tuesday. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market cap of $895.04 million, a PE ratio of -3.29 and a beta of 0.08. The company has a 50-day moving average of $13.16 and a two-hundred day moving average of $13.39.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.25. The company had revenue of $1.57 million for the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Woodline Partners LP lifted its position in shares of uniQure by 25.0% during the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after acquiring an additional 35,175 shares during the last quarter. 683 Capital Management LLC boosted its stake in uniQure by 1.6% in the 1st quarter. 683 Capital Management LLC now owns 1,550,000 shares of the biotechnology company’s stock worth $16,430,000 after purchasing an additional 25,000 shares during the period. Vestal Point Capital LP raised its stake in uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after purchasing an additional 1,767,572 shares during the period. Birchview Capital LP lifted its holdings in shares of uniQure by 343.5% in the first quarter. Birchview Capital LP now owns 88,697 shares of the biotechnology company’s stock valued at $940,000 after purchasing an additional 68,697 shares in the last quarter. Finally, Nantahala Capital Management LLC lifted its holdings in shares of uniQure by 3.8% in the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company’s stock valued at $29,213,000 after purchasing an additional 101,598 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.